| Notice of Special Interest: Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed) |
NOT-OD-22-202 |
|
Clinical Trial Not Allowed |
04/16/2025 |
Nancy J. Emenaker, Ph.D., RDN, LD, FAND |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research |
PAR-22-099 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
05/08/2025 |
Richard Mazurchuk, Ph.D. |
| Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers |
NOT-CA-23-004 |
|
|
07/02/2025 |
Matthew Young, Ph.D. |
| Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes |
PAR-22-131 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
09/08/2025 |
Richard Mazurchuk, Ph.D. |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-23-314 (UH3 Clinical Trials Not Allowed) |
UH3 |
|
10/15/2026 |
Sudhir Srivastava, Ph.D., M.P.H. |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-23-313 (UH2/UH3 Clinical Trial Not Allowed) |
UH2, UH3 |
Clinical Trial Not Allowed |
10/15/2026 |
Sudhir Srivastava, Ph.D., M.P.H. |